Armata Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2005-01-01
- Employees
- 66
- Market Cap
- $87M
- Website
- http://www.armatapharma.com
- Introduction
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
- Conditions
- Lung InfectionNon-cystic Fibrosis BronchiectasisPseudomonas Aeruginosa
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05616221
- Locations
- 🇺🇸
Velocity Clinical Research, Mobile, Alabama, United States
🇺🇸Southern California Institute for Respiratory Diseases Cedars-Sinai West Tower, Los Angeles, California, United States
🇺🇸UCONN Health, Farmington, Connecticut, United States
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects with S. Aureus Bacteremia
- Conditions
- BacteremiaBacteremia StaphStaphylococcus AureusBacteremia Due to Staphylococcus AureusStaphylococcus Aureus Bacteremia
- Interventions
- Other: Placebo
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05184764
- Locations
- 🇺🇸
Banner University Medical Center, Tucson, Arizona, United States
🇺🇸University of California, San Diego (UCSD) - Medical Center, La Jolla, California, United States
🇺🇸University of Southern California Keck School of Medicine, Los Angeles, California, United States
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
- Conditions
- PseudomonasCystic FibrosisPseudomonas AeruginosaLung InfectionLung Infection Pseudomonal
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04596319
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸St. Luke's Cystic Fibrosis Center of Idaho, Boise, Idaho, United States
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Registration Number
- NCT03395743
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Registration Number
- NCT03395769
- Prev
- 1
- 2
- 3
- Next
News
Armata's Bacteriophage Therapy Shows Promising Results in Treating Staphylococcus aureus Bacteremia
Armata Pharmaceuticals' Phase 1b/2a diSArm trial demonstrated that AP-SA02, a novel intravenous bacteriophage therapy, met all primary endpoints for safety, tolerability, and clinical response in complicated Staphylococcus aureus bacteremia.
Non-Cystic Fibrosis Bronchiectasis Market Expected to Reach USD 7.5 Billion by 2035, Driven by Novel Therapies
The Non-Cystic Fibrosis Bronchiectasis (NCFB) market is projected to grow from USD 1.7 billion in 2024 to USD 7.5 billion by 2035, representing a robust CAGR of 14.62%.
Phage Therapies and Novel Molecules Show Promise in Treating Chronic Pseudomonas Aeruginosa Pulmonary Infections
• Armata Pharmaceuticals' AP-PA02, a therapeutic phage cocktail, is currently in Phase II trials for bronchiectasis and pseudomonal infections, targeting *P. aeruginosa* in respiratory infections. • BiomX's BX004, a phage therapy, is in Phase I/II trials for chronic *Pseudomonas aeruginosa* pulmonary infections in cystic fibrosis patients, demonstrating activity against antibiotic-resistant strains. • The pipeline for chronic *Pseudomonas aeruginosa* pulmonary infections includes over 12 drugs in various stages of clinical development, with companies like Gilead and Respirion also involved.
NCFB Pipeline Shows Promise with Over 15 Companies Developing New Therapies
• The non-cystic fibrosis bronchiectasis (NCFB) market is experiencing growth due to rising prevalence and increased awareness, leading to early diagnosis and treatment. • Over 15 companies are actively developing more than 15 NCFB drugs, aiming to improve the treatment landscape for this chronic lung condition. • Key players like Insmed, AstraZeneca, and Verona Pharma are advancing promising therapies such as brensocatib, benralizumab and ensifentrine through clinical trials. • Recent clinical trial milestones, including Phase III results for brensocatib and Phase II enrollment for AP-PA02, signal progress in addressing unmet needs in NCFB treatment.
Iovance's MDA-TIL Trial Terminated, Sention's ST-1891 Phase II Completed
Iovance Biotherapeutics' MDA-TIL Phase II trial was terminated due to lack of efficacy, significantly decreasing its Phase Transition Success Rate (PTSR) in ovarian, colorectal, and pancreatic cancers.